A Phase 1 Study of the Safety and Immunogenicity of Plant-Derived Recombinant Protective Antigen (rPA) Anthrax Vaccine in Healthy Adults

Trial Profile

A Phase 1 Study of the Safety and Immunogenicity of Plant-Derived Recombinant Protective Antigen (rPA) Anthrax Vaccine in Healthy Adults

Completed
Phase of Trial: Phase I

Latest Information Update: 21 May 2016

At a glance

  • Drugs PA83 FhCMB (Primary)
  • Indications Anthrax
  • Focus Adverse reactions
  • Sponsors Fraunhofer USA Center for Molecular Biotechnology
  • Most Recent Events

    • 10 May 2016 Status changed from active, no longer recruiting to completed.
    • 17 Jun 2015 Status changed from recruiting to active, no longer recruiting,as reported by ClinicalTrials.gov.
    • 17 Jun 2015 Planned primary completion date changed from 1 May 2015 to 1 Jul 2015, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top